Klaus Klumpp, PhD.

Co-Founder and President of Riboscience

He previously served as Vice President, Discovery Research at Novira Therapeutics Inc., contributing to the development of new treatments for chronic Hepatitis B infection. Novira Therapeutics Inc. was acquired by Johnson & Johnson in 2015. Klaus led research and development activites at Roche in the area of infectious diseases between 1997 and 2013, most recently as Vice President and Global Head of Virology Discovery. He also held research fellow positions at GlaxoWellcome Research and Development, the European Molecular Biology Laboratory (EMBL) and the Max-Planck Institute for Biophysics.